Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany.
German Center for Diabetes Research (DZD), Neuherberg, Germany.
Diabetologia. 2021 Apr;64(4):814-825. doi: 10.1007/s00125-020-05362-7. Epub 2021 Jan 15.
AIMS/HYPOTHESIS: Studies suggest decreased mortality risk among people who are overweight or obese compared with individuals with normal weight in type 2 diabetes (obesity paradox). However, the relationship between body weight or weight change and microvascular vs macrovascular complications of type 2 diabetes remains unresolved. We investigated the association between BMI and BMI change with long-term risk of microvascular and macrovascular complications in type 2 diabetes in a prospective cohort study.
We studied participants with incident type 2 diabetes from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort, who were free of cancer, cardiovascular disease and microvascular disease at diagnosis (n = 1083). Pre-diagnosis BMI and relative annual change between pre- and post-diagnosis BMI were evaluated in multivariable-adjusted Cox models.
There were 85 macrovascular (myocardial infarction and stroke) and 347 microvascular events (kidney disease, neuropathy and retinopathy) over a median follow-up of 10.8 years. Median pre-diagnosis BMI was 29.9 kg/m (IQR 27.4-33.2), and the median relative annual BMI change was -0.4% (IQR -2.1 to 0.9). Higher pre-diagnosis BMI was positively associated with total microvascular complications (multivariable-adjusted HR per 5 kg/m [95% CI]: 1.21 [1.07, 1.36], kidney disease 1.39 [1.21, 1.60] and neuropathy 1.12 [0.96, 1.31]) but not with macrovascular complications (HR 1.05 [95% CI 0.81, 1.36]). Analyses according to BMI categories corroborated these findings. Effect modification was not evident by sex, smoking status or age groups. In analyses according to BMI change categories, BMI loss of more than 1% indicated a decreased risk of total microvascular complications (HR 0.62 [95% CI 0.47, 0.80]), kidney disease (HR 0.57 [95% CI 0.40, 0.81]) and neuropathy (HR 0.73 [95% CI 0.52, 1.03]), compared with participants with a stable BMI; no clear association was observed for macrovascular complications (HR 1.04 [95% CI 0.62, 1.74]). The associations between BMI gain compared with stable BMI and diabetes-related vascular complications were less apparent. Associations were consistent across strata of sex, age, pre-diagnosis BMI or medication but appeared to be stronger among never-smokers compared with current or former smokers.
CONCLUSIONS/INTERPRETATION: Among people with incident type 2 diabetes, pre-diagnosis BMI was positively associated with microvascular complications, while a reduced risk was observed with weight loss when compared with stable weight. The relationships with macrovascular disease were less clear.
目的/假设:研究表明,与体重正常的 2 型糖尿病患者相比,超重或肥胖的患者死亡率风险较低(肥胖悖论)。然而,体重或体重变化与 2 型糖尿病的微血管和大血管并发症之间的关系仍未得到解决。我们在一项前瞻性队列研究中调查了 BMI 及 BMI 变化与 2 型糖尿病患者长期微血管和大血管并发症风险之间的关系。
我们研究了来自欧洲癌症前瞻性调查与营养(EPIC)-波茨坦队列的新发 2 型糖尿病患者,这些患者在诊断时无癌症、心血管疾病和微血管疾病(n=1083)。在多变量调整的 Cox 模型中评估了预诊断 BMI 以及预诊断和诊断后 BMI 之间的相对年度变化。
在中位随访 10.8 年期间,发生了 85 例大血管(心肌梗死和中风)和 347 例微血管事件(肾脏疾病、神经病变和视网膜病变)。预诊断时的 BMI 中位数为 29.9kg/m²(IQR 27.4-33.2),相对年度 BMI 变化中位数为-0.4%(IQR-2.1 至 0.9)。较高的预诊断 BMI 与总微血管并发症呈正相关(每增加 5kg/m²的多变量调整 HR [95%CI]:1.21[1.07, 1.36],肾脏疾病 1.39[1.21, 1.60]和神经病变 1.12[0.96, 1.31]),但与大血管并发症无关(HR 1.05[95%CI 0.81, 1.36])。根据 BMI 类别进行的分析证实了这些发现。按性别、吸烟状况或年龄组分层后,未观察到效应修饰。根据 BMI 变化类别进行的分析表明,BMI 下降超过 1%表明总微血管并发症风险降低(HR 0.62[95%CI 0.47, 0.80])、肾脏疾病(HR 0.57[95%CI 0.40, 0.81])和神经病变(HR 0.73[95%CI 0.52, 1.03]),与 BMI 稳定的参与者相比;与大血管并发症(HR 1.04[95%CI 0.62, 1.74])无明显关联。与 BMI 稳定相比,BMI 增加与糖尿病相关血管并发症的相关性不太明显。这些关联在性别、年龄、预诊断 BMI 或药物治疗的各个亚组中是一致的,但与当前或曾经吸烟者相比,从不吸烟者的关联似乎更强。
结论/解释:在患有 2 型糖尿病的新发患者中,预诊断 BMI 与微血管并发症呈正相关,而与体重稳定相比,体重减轻与风险降低相关。与大血管疾病的关系不太清楚。